Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

He, Xinlin; Zhou, Ying; Lu, Huanzi; Li, Qunxing; Wang, Zhi

doi:10.1038/s41598-020-59608-w

Cited by 18 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among clinicopathological characteristics, high expression of VISTA was significantly associated with high numbers of CD8+ TILs (risk ratio = 1.80, 95% CI 1.41–2.31, p < 0.001). 74 CD8+ TILs have already been related to antitumoral properties in different studies involving patients with hepatocellular carcinoma, 75 cervical and ovarian cancer, 76–78 squamous-cell head and neck carcinoma, 79 and lung cancer, 80 thus potentially indirectly supporting the positive prognostic role of VISTA as a biomarker.…”

Section: Discussionmentioning

confidence: 93%

“…A systematic review and meta-analysis of 10 studies (2,440 patients) correlated the value of VISTA with clinicopathological features and patient’s outcome endpoints including OS and disease-specific survival (DSS), via pooled HR and 95% confidence interval (CI). 74 High expression of VISTA (cut-off differently defined among studies) was associated with better OS compared to low expression (HR = 0.75, 95% CI 0.66–0.86, p < 0.001), but no association with DSS was observed (HR = 1.57, 95% CI 0.71–3.48, p = 0.268). Among clinicopathological characteristics, high expression of VISTA was significantly associated with high numbers of CD8+ TILs (risk ratio = 1.80, 95% CI 1.41–2.31, p < 0.001).…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

VISTA: A Promising Target for Cancer Immunotherapy?

Tagliamento¹,

Agostinetto²,

Borea³

et al. 2021

ITT

View full text Add to dashboard Cite

Agents targeting the B7 family co-inhibitory receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1), or its ligand (PD-L1), have a pivotal role in clinical practice. V-domain Ig suppressor of T-cell activation (VISTA) is a protein highly conserved between species, with a similar amino acid sequence to the B7 family members, characterized by a particularly structural homology to PD-1. It has been counted as an emerging target within the list of novel targetable immune checkpoints in oncology. Physiologically, VISTA exerts a regulatory function on the immune system at several levels, particularly by modulating T cells activation. Its altered activity plays a role in many autoimmune diseases, and its expression has been found to be prognostically implicated in different cancer types in preclinical models. We hereby present the main evidence on the value of VISTA as an immune checkpoint in solid and hematological malignancies. We also review its value as a potential target for cancer immunotherapy, by reporting the results of Phase I and II clinical trials assessing the use of drugs targeting VISTA. The complexity of its pathway, along with some unclear biological aspects concerning its molecular interactions, currently represent a limit to the applicability of VISTA as an effective biomarker for immunotherapy in oncology. A deeper characterization of this immune checkpoint may help defining its value within immune signatures of solid and hematological malignancies, and to design future therapeutic strategies.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 96%

VISTA: A Promising Target for Cancer Immunotherapy?

Tagliamento¹,

Agostinetto²,

Borea³

et al. 2021

ITT

View full text Add to dashboard Cite

show abstract

“…Previous studies indicated that VISTA was detected frequently in the TME of several solid tumors (Deng et al 2016;He et al 2020;Liao et al 2018;Rosenbaum et al 2020). In this study, we extensively explored the expression of VISTA in 223 PDAC tumor tissues by IHC staining of each large section.…”

Section: Vista Expression In Pdacmentioning

confidence: 99%

Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer

Hou

Pan

Fei

et al. 2020

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Objective V-domain Ig suppressor of T cell activation (VISTA) is a novel immune checkpoint protein that belongs to the B7 family. The aim of this study was to investigate the prognostic significance and therapeutic potential of VISTA in patients with pancreatic cancer. Methods Using immunohistochemistry (IHC), we examined the expression of VISTA and demonstrated the associations between the VISTA and overall survival in 223 PDAC patients from 2 different unrelated retrospective cohorts. The multiplex immunofluorescence was performed to illuminate the relationship between VISTA expression and tumor-infiltrating immune cell subclusters of PDAC. We also verified the findings in The Cancer Genome Atlas (TCGA) dataset. The anti-tumor effect of anti-VISTA therapy was studied by the mouse model with liver metastases of PDAC. Results The VISTA protein was highly expressed in 25.6% of tumor cells (TCs), 38.1% of immune cells, and 26.0% of endothelial cells in 223 PDAC tumor tissues. VISTA expression in TCs was significantly associated with prolonged overall survival. Multiplex immunofluorescence analysis revealed that VISTA level was positively correlated with CD68+ macrophages, CD3+ T cells, and CD19+ B cells in PDAC. However, a higher expression level of VISTA was detected in tumor-infiltrating CD68+ macrophages than in CD3+ T and CD19+ B cells. Furthermore, anti-VISTA antibody treatment significantly reduced the number of metastatic nodules in livers of mouse models of PDAC with liver metastases. Conclusion VISTA expressed in TCs is associated with a favorable prognosis in PDAC. Moreover, immunotherapy with anti-VISTA antibodies may potentially be an effective treatment strategy against PDAC.

show abstract

“…However, VISTA overexpression has been associated with the inferior overall survival of patients with oral squamous cell carcinoma ( 77 ). A recent meta-analysis has shown that VISTA overexpression is associated with improved overall survival and increased tumor-infiltrating cytotoxic T lymphocytes in cancer patients ( 82 ).…”

Section: Vista As a Prognostic Factor In Cancersmentioning

confidence: 99%

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead

et al. 2021

View full text Add to dashboard Cite

Immune checkpoints (ICs) have pivotal roles in regulating immune responses. The inhibitory ICs in the tumor microenvironment (TME) have been implicated in the immune evasion of tumoral cells. Therefore, identifying and targeting these inhibitory ICs might be critical for eliminating tumoral cells. V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel inhibitory IC that is expressed on myeloid cells, lymphoid cells, and tumoral cells; therefore, VISTA can substantially regulate innate and adaptive anti-tumoral immune responses. Besides, growing evidence indicates that VISTA blockade can enhance the sensitivity of tumoral cells to conventional IC-based immunotherapy, e.g., cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors. In this regard, the current study aimed to review the current evidence about the structure and expression pattern of VISTA, its role in TME, the clinicopathological significance of VISTA, and its prognostic values in various cancers. Besides, this review intended to collect the lessons from the recent pre-clinical and clinical studies and propose a strategy to overcome tumor immune-resistance states.

show abstract

Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

Abstract: Two investigators (X.L.H. and Y.Z) independently checked all eligible articles. They reached an agreement via mutual discussion to solve any discrepancies.

Cited by 18 publications

References 30 publications

VISTA: A Promising Target for Cancer Immunotherapy?

VISTA: A Promising Target for Cancer Immunotherapy?

Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead

Contact Info

Product

Resources

About